Pharmacological closure of patent ductus arteriosus: Effects on pulse pressure and on endothelin-1 and vasopressin excretion

American Journal of Perinatology

Volumn 25, Issue 6, 2008, Pages 353-358

  Zanardo, Vincenzo ^a   Vedovato, Stefania ^a   Chiozza, Laura ^a   Faggian, Diego ^a   Favaro, Flaviano ^a   Trevisanuto, Daniele ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

AVP; ET 1; Ibuprofen; Indomethacin; PDA; Pulse pressure

Indexed keywords

ARGIPRESSIN; ENDOTHELIN 1; IBUPROFEN; IBUPROFEN LYSINE; INDOMETACIN; LYOMETACEN; NONSTEROID ANTIINFLAMMATORY AGENT; PORACTANT; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG TREATMENT FAILURE; DUCTUS ARTERIOSUS OBLITERATION; FEMALE; HEART LEFT RIGHT SHUNT; HORMONE BLOOD LEVEL; HUMAN; LUNG CIRCULATION; MALE; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN; PATENT DUCTUS ARTERIOSUS; PREDICTION; PREMATURITY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARGININE VASOPRESSIN; BLOOD PRESSURE; DUCTUS ARTERIOSUS, PATENT; ENDOTHELIN-1; FEMALE; HUMANS; IBUPROFEN; INDOMETHACIN; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; MALE; TREATMENT FAILURE;

EID: 52249119171     PISSN: 07351631     EISSN: 10988785     Source Type: Journal    
DOI: 10.1055/s-2008-1078763     Document Type: Article

References (33)

1. Endo A, Ayusawa M, Minato M, Takalda M, Takahashi S, Harada K. Physiologic significance of nitric oxide and endothelin-1 in circulatory adaptation. Pediatr Int 2000;42: 26-30
2. Ramin SM, Porter JC, Gilstrap LC, Rosenfeld CR. Stress hormones and acid-base status of human fetuses at delivery. J Clin Endocrinol Metab 1991;73:182-186
3. Bernstein D. Acyanotic congenital heart diseases: the left-toright shunt lesions. In: Behrman RE, Kliegman RM, Jenson HB, eds. Nelson Textbook of Pediatrics. 16th ed. Philadelphia: WB Saunders; 2000:1372-1373
4. Lubetzky R, Mendel D, Mimouni FB, et al. Indomethacininduced early patent ductus arteriosus closure cannot be predicted by a decrease in pulse pressure. Am J Perinatol 2004;21:257-261
5. Evans N, Moorcraft J. Effect of patency of ductus arteriosus in blood pressure in very preterm infants. Arch Dis Child 1992;67:1169-1173
6. Evans N, Iyer P. Changes in blood pressure after treatment of patent ductus arteriosus with indomethacin. Arch Dis Child 1993;24:584-587
7. Whelton A. Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics. Am J Ther 2000;7:63-74
8. Tsukahara H, Sekine K, Miura M, et al. Vasoactive and natriuretic mediators in umbilical cord blood: a report of our observation and review of the literature. Early Hum Dev 2002;69:57-64
9. Aranda JV, Varvarigou A, Beharry K, et al. Pharmacokinetics and protein binding of intravenous ibuprofen in the premature newborn infant. Acta Paediatr 1997;86:289-293
10. Moore P, Book MM, Heymann MA. Patent ductus arteriosus. In: Allen HD, Gutgessel HP, Clark EB, Driscol DJ, eds. Moss and Adam's Hearth Disease in infants, Childhood, and Adolescent. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2001:652-669
11. Ratner I, Perelmuter B, Toews W, Whitfields J. Association of low systolic and diastolic blood pressure with significant patent ductus arteriosus in the very low birth weight infant. Crit Care Med 1985;13:497-500
12. Lago P, Bettiol T, Salvadori S, et al. Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomized controlled trial. Eur J Pediatr 2002;161:202-207
13. Guignard JP. The adverse renal effect of prostaglandin-synthesis inhibitors in the newborn rabbit. Semin Perinatol 2002;26:398-405
14. Johnson GL, Breart GL, Gewitz MH, et al. Echocardiographic characteristics of premature infants with patent ductus arteriosus. Pediatrics 1983;72:864-871
15. Lee J, Rajadurai VS, Tan KW. Blood pressure standards for low birthweight infants during the first day of life. Arch Dis Child Fetal Neonatal Ed 1999;81:168-170
16. Sulyok E, Ertl T, Adamovits K, Hovanyovszky S, Rascher W. Urinary endothelin excretion in the neonate: influence of maturity and perinatal pathology. Pediatr Nephrol 1993;7: 881-885
17. Bhat R, John E, Chari G, et al. Renal actions of endothelin-1 in newborn piglets: dose-effect relation and the effects of receptor antagonist (BQ-123) and cyclooxygenase inhibitor (indomethacin). J Lab ClinMed 1995;126: 458-469
18. Munger KA, Takahashi K, Ebert J, Badr KF. Role of cyclooxygenase products in mediating renal responses to endothelin. Kidney Int 1990;37:375
19. Haynes WG, Ferro CI, O'Kane KP, Somerville D, Lomax CC, Webb DI. Systemic endothelin blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 1996;93:1960-1970
20. Chou S-Y, Porush IG. Renal action of endothelin-1 and endothelin-3: interaction with the prostaglandin system and nitric oxide. Am J Kidney Dis 1995;26:116-123
21. Kojima T, Isozaki FY, Takedatsu A, Oho Y, Kohayashi Y. Plasma endothelin-1 like immunoreactivity levels in neonates. Eur J Pediatr 1992;151:913-915
22. Ivy DD, Parker TA, Kinsella JP, Abman SH. (1998) Endothelin A receptor blockade decreases pulmonary vascular resistance in premature lambs with hyaline membrane disease. Pediatr Res 1998;44:175-180
23. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin 1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991;114:464-469
24. de Vroomen M, Lopes Cardozo RH, Stendijk P, Frolich M, Boan J, van Bel F. Endothelin-1 plasma concentration increases in the early phase of pulmonary hypertension development during respiratory distress syndrome: a study in newborn lambs. Early Hum Dev 2001;63:9-21
25. Miller WL, Redfield MM, Burnett JC. Integrated cardiac, renal and endocrine actions of endothelin. J Clin Invest 1989; 83:317-320
26. Dobyns EL, Eells P, Griebel JL, Abman SH. Elevated plasma endothelin-1 and cytokine levels in children with severe acute respiratory distress syndrome. J Pediatr 1999;135:246-249
27. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990;348:730-732
28. Sakurai T, Yanagisawa M, Takuwa Y, et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990;348:732-735
29. Shetty SS, Toshikazu O, Webb RL, DelGrande D, Lapp RW. Functionally distinct endothelin b receptors in vascular endothelium and smooth muscle. Biochem Biophys Res Commun 1993;191:459-464
30. Meyer S, Gottschling S, Baghai A, Wurm D, Gortner L. Arginine-vasopressin in catecholamine-refractory septic versus non-septic shock in extremely low birth weight infants with acute renal injury. Crit Care 2006;10:71-74
31. Barrett LK, Singer M, Clapp LH. Vasopressin: mechanisms of action on the vasculature in health and in septic shock. Crit Care Med 2007;35:33-40
32. Ervin MG, Ross MG, Leake RD, Fisher DA. V1- and V2-receptor contributions to ovine fetal renal and cardiovascular responses to vasopressin. Am J Physiol 1992;262:R636-643
33. Shi L, Guerra C, Yao J, Xu Z. Vasopressin mechanis-mmediated pressor responses caused by central angiotensin II in the ovine fetus. Pediatr Res 2004;56:756-762